News

Sarepta stock falls after FDA places clinical hold on gene therapy trials

Investing.com -- Sarepta Therapeutics Inc (NASDAQ: SRPT) stock tumbled 10% following the announcement that the U.S. Food and Drug Administration has placed a clinical hold on the company’s ...
InvestorsHub on MSN1h

Elevance Health Shares Touch 52-Week Low Amid Sector Headwinds and Medicaid Pressures

Shares of Elevance Health Inc. (NYSE:ELV) dropped to a new 52-week low of $275.60, reflecting a turbulent year for the ...
InvestorsHub on MSN1h

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

Hiding Weather Data Harms More Than Hurricane Forecasts

The Trump administration’s decision to stop sharing military satellite information with meteorologists will accelerate the ...

NXP Semiconductors Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Evercore ISI Group analyst Mark Lipacis maintained an Outperform rating and increased the price target from $237 to $289 on ...

India markets regulator allows Jane Street to restart trading, sources say

India's markets regulator has allowed Jane Street to restart trading after the U.S. high-frequency trading firm deposited ...
Investing Snacks6h

Merck Takes a Hit: Analysts Slash Q2 Earnings Forecast

Leerink Partnrs has trimmed its Q2 2025 earnings estimate for Merck & Co., Inc., foreseeing a dip to $1.96 per share from ...